Drug intelligence / Profile preview

Huoxue Changzhi granule

Development stage: Unknown
Lead developer: Xuanwu Hospital
Administration: Oral

Overview

Huoxue Changzhi granule is a Traditional Chinese Medicine (TCM) formula developed by Xuanwu Hospital of Capital Medical University for the treatment of generalized anxiety disorder (GAD). The formula is designed based on the TCM principle of "invigorating blood and smoothing the mind" (Huoxue Changzhi), addressing the pathological mechanisms of anxiety as defined in traditional practice. It is currently being evaluated in clinical trials in China as part of an optimized TCM regimen, where it is compared against standard pharmacotherapy such as buspirone. The drug is typically administered orally in a granule dosage form and is often used within a syndrome-differentiation framework to target specific TCM patterns associated with anxiety.

Other names: Huoxue Changzhi Keli

Beyond the preview

Go deeper on Huoxue Changzhi granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huoxue Changzhi granule.

Explore the full profile